Pregnancy outcome in women with antiphospholipid antibodies.
The association of antiphospholipid antibodies (APA) or lupus anticoagulant (LA) and recurrent fetal loss (RFL) is well established; however, the spectrum of pregnancy outcome in relation to various therapeutic approaches versus placebo is unknown. We studied 49 women with RFL, 14 with immune thrombocytopenia (ITP) 13 of whom without a history of RFL, and 32 controls (all in the first trimester of pregnancy) for the presence of APA. Tests for APA were positive in 15/49 women with RFL (30%), 6/14 ITP (43%) and 2/32 controls (6%). Treatment in the APA positive patients consisted of: no treatment for the 8 patients who had no history of RFL (Group A; all 34 previous pregnancies successful), aspirin alone (Group B, 5 patients; all 30 previous pregnancies unsuccessful), aspirin with prednisolone (Group C, 9 patients; 69/80 previous pregnancies unsuccessful), or aspirin, prednisolone and immunoglobulin G for resistant cases (Group D, 4 patients, previously in Group C). 10/11 (90.9%), 3/7 (43%), 7/13 (53.8%) and 4/7 (57.1%) pregnancies were successful in Group A, B, C and D, respectively. There was a total of 19/45 (42%) failures including 3 pregnancies in one patient who failed to respond to all forms of therapy. This open study with small subgroups of patients draws attention to a wide range of pregnancy outcome in women with APA and to the fact that APA may serve only as a marker for a wide range of pathological conditions with variable degrees of disease severity. More studies are, however, needed to explore the real mechanism of RFL in women with APA and RFL, especially those who are resistant to therapy.
al-Momen
A K
AK
Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Moghraby
S A
SA
el-Rab
M O
MO
Gader
A M
AM
al-Balla
S R
SR
al-Meshari
A A
AA
al-Nuaim
L
L
D000026:Abortion, Habitual / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000032:analysis*; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy / Q000276:immunology; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D012016:Reference Values; D013921:Thrombocytopenia / Q000188:drug therapy / Q000276:immunology
D017152:Antibodies, Antiphospholipid; D007074:Immunoglobulin G; D011239:Prednisolone; D001241:Aspirin